China carries roughly half the world's liver-cancer burden — and built the deepest playbook for it. Resection, ablation, TACE, targeted and immunotherapy are sequenced by the same multidisciplinary team inside one hospital, so a liver tumour that meets a dead end in one modality is immediately routed to another. It is the archetypal 'China leads' cancer.
| Option | Best suited for | What it means in practice |
|---|---|---|
| Anatomic resection (open or laparoscopic) | Early HCC with adequate liver reserve | ICG-guided anatomy; published 5-year survival above 60% for small HCC. |
| Thermal ablation (RFA / MWA) | Tumours under 3 cm, poor-reserve livers | Curative-intent for small tumours without cutting. |
| TACE (+ combination strategies) | Multinodular intermediate disease | The backbone for stage B; combined with ablation for larger lesions. |
| Immunotherapy + anti-VEGF systemic therapy | Advanced disease | The combination largely defined by Chinese-led pivotal trials. |
| Typical China cost (reference only) | US$10,000–30,000 per treatment phase (resection, TACE course or first-line systemic therapy); full pathways vary widely |
|---|---|
| Typical in-hospital stay | Resection: 7–12 days; TACE: 2–4 days per session; systemic therapy: outpatient |
| Return-to-travel timeline | Resection: fly home at 3–4 weeks; TACE/immunotherapy cycles often partially managed at home |
Costs are indicative ranges for international self-pay patients at major Chinese hospitals; final quotes depend on the hospital, implant/medication choice and case complexity. WellVoyage locks a written all-in quote before you commit.
A 4 cm tumour and a liver already stiffened by fatty-liver disease. Sequential TACE plus ablation in Guangzhou converted an inoperable lesion into a controlled one; at three years, imaging shows no viable tumour.
Recurrence after a Milan resection at home. Chinese multimodal sequencing — ablation for small lesions, TACE for the larger, systemic backstop — has kept him functional for four further years.
Told she was beyond transplant criteria in London. Conversion therapy in China — combined treatment that shrank the tumour — brought her back inside them; she is now listed at home with a treated, smaller tumour.
A 5 cm tumour in a cirrhotic liver. Resection with meticulous volumetric planning preserved enough liver to live well with; his hepatitis is suppressed and his AFP is undetectable.
Tumour thrombus made surgery off-limits by classic criteria. Chinese radiotherapy combined with targeted therapy cleared the thrombus; his case is now the one his home oncologist quotes at conferences.
A country with one of the world's highest HCC burdens, and a patient whose thrombus and tumour shrank on Chinese combined therapy before resection. Antivirals cured the cause; surgery removed the consequence.
An emergency admission that became a staged success: embolisation first, resection six weeks later. He arrived by ambulance and left with a carry-on.
It makes antiviral control part of the cancer treatment, and Chinese centres manage HBV-related HCC every day — antiviral suppression before, during and after therapy is standard there in a way smaller programmes often overlook.
Commonly, yes — the Chinese team builds a written plan (with drug names, doses, schedule) that your home oncologist executes; WellVoyage translates the whole file so nothing is lost in handover.
WellVoyage translates your records, obtains independent specialist opinions, and locks a transparent written quote — before you book a flight.
Start with a Free Case Review →